Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the European Union In Vitro Diagnostic Regulation (IVDR) approval of ...

US FDA grants priority review for Roche’s Tecentriq for a certain type of stage III colon cancer: Basel, Switzerland Friday, June 12, 2026, 14:00 Hrs [IST] Swiss pharma major Ro ...

Adding Opdivo (nivolumab) and Yervoy (ipilimumab) to chemotherapy did not improve how long patients with HER2-negative ...

Akeso announced that ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit with a hazard ratio of 0.66 compared to PD-1 plus chemotherapy in first-line squamous ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or ...

Prominently featured in The Inner Circle, Cha-Mei Tang is acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for her contributions to Pioneering Cancer Diagnostics and Cancer ...

Akeso, Inc. (9926.HK) (Akeso or the Company) today announced that ivonescimab, the Company's first-in-class PD-1/VEGF ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Entering June in the Wrong Direction. Summit Therapeutics ...